United Kingdom (UK)
Recombinant monoclonal antibody to hemagglutinin H1. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the phage display antibody 3978.
Alternative Name(s) of Target: H1; haemagglutinin H1; #3978
Immunogen: This antibody was raised by sequencing DNA from PMBCs from humans immunized with the split-virion (IIV) quadrivalent seasonal influenza vaccine Fluzone in 2016-2017.
Specificity: This antibody is specific for the hemagglutinin protein of influenza. Hemagglutinin is a homotrimeric glycoprotein found on the surface of influenza viruses and is integral to its infectivity.
Application Notes: ELISA on recombinant hemagglutinnin has proven the specificity of the human version of this antibody. Further, hemagglutination inhibition assays (HAIs) were also performed to measure functional antibodies capable of inhibiting virus agglutination. For this assay the human antibody was mixed with the influenza virus to which erythrocytes were added. Then, the HAI titer was determined by the reciprocal dilution of the last well that contained non-agglutinated RBCs. Finally, human PBMCs were stained for flow cytometry using the human version of this antibody (Forgacs et al, 2021; pmid:33617543).
Antibody first published in:
Forgacs et al. Convergent antibody evolution and clonotype expansion following influenza virus vaccination PLoS One. 2021; 16(2): e0247253. PMID:33617543
Note on publication:
PBMCs were collected from 17 human participants vaccinated with the split-inactivated influenza virus vaccine during the 2016–2017 influenza season. A combination of Immune Repertoire Capture (IRCTM) technology and IgG sequencing was performed on ~7,800 plasmablast (PB) cells and preferential IgG heavy-light chain pairings were investigated.